AKESO(09926) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

09926 AKESO

Watchlist

76.200
+1.600+2.14%

Not Open Mar 31 16:08 CST

68.40BMarket Cap-123.10P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Akeso Reports FY Results
Seeking Alpha13:26 ET
Akeso Swings to Loss in 2024
MT NewswiresMar 31 07:07 ET
Zhitong Hong Kong stocks early news | The financing plans of the four major Banks are announced, and Gold has risen for four consecutive weeks, setting a new historical high.
Bank Of China, China Construction Bank Corporation, Bank Of Communications, and Postal Savings Bank Of China announced the plan to issue A-shares to specific entities, introducing strategic investment from the Ministry of Finance.
Zhitong FinanceMar 30 19:35 ET
Express News | Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape With Bispecific Antibodies
ReutersMar 30 14:32 ET
Press Release: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape With Bispecific Antibodies
Dow JonesMar 30 14:32 ET
AKESO: The sharp decline in commercialization licensing revenue has led to a shift from profit to loss, while sales of Innovative Drugs continue to grow rapidly | Interpretations
① Due to a significant decrease in commercial revenue, AKESO is expected to turn from profit to loss in 2024. ② The commercialization of Innovative Drugs is continuously being promoted, and sales revenue is maintaining rapid growth.
cls.cnMar 30 11:07 ET

Comments

Jerry Kronenberg

Jun 5, 2024 02:23

Columns Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally

$Summit Therapeutics (SMMT.US)$ fell nearly 20% Tuesday as the biotech firm's stock continued to give back part of a 280%+ rally that it saw last Thursday on positive study results for its candidate cancer drug ivonescimab.
SMMT sank to as low as $7.26 intraday, down 17.9% on the session and 35.5% from its $11.25 intraday peak last Thursday.
Summit had rallied 284% intraday last Thursday, rising to as high as $11.25...

Moomoo AI

Mar 21, 2024 07:14

Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.

Akeso, Inc. Just Recorded A 8.5% EPS Beat: Here's What Analysts Are Forecasting Next

Moomoo AI

Mar 15, 2024 06:41

Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.

Akeso, Inc.'s (HKG:9926) 25% Price Boost Is Out Of Tune With Revenues

Spinee

Jan 17, 2024 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Dec 28, 2023 10:11

Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.